The Technical Analyst
Merrimack Pharmaceuticals [MACK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Merrimack Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.27% $14.72
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 213.91 mill |
| EPS: | -0.0800 |
| P/E: | -184.00 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 14.53 mill |
| Avg Daily Volume: | 0.128 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -184.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -31.30x |
| Company: PE -184.00 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.419 (-97.15%) $-14.30 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 14.59 - 14.87 ( +/- 0.93%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-28 | Andersen Eric | Buy | 857 | Common Stock |
| 2023-12-26 | Andersen Eric | Buy | 48 693 | Common Stock |
| 2023-12-07 | Andersen Eric | Buy | 76 384 | Common Stock |
| 2023-12-07 | Andersen Eric | Buy | 24 666 | Common Stock |
| 2023-11-17 | Andersen Eric | Buy | 235 | Common Stock |
| INSIDER POWER |
|---|
| 99.77 |
| Last 100 transactions |
| Buy: 1 159 920 | Sell: 7 000 |
Forecast:
16:00 - $14.73
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $14.73
Forecast 2: 16:00 - $14.73
Forecast 3: 16:00 - $14.73
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.72 (0.27% ) |
| Volume | 0.0754 mill |
| Avg. Vol. | 0.128 mill |
| % of Avg. Vol | 58.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MACK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-03-27 16:30:00 - Press Release
Merrimack Receives $225 Million Milestone Payment From Ipsen
Cambridge, mass.--(business wire)--merrimack pharmaceuticals, inc. (nasdaq: mack) (“merrimack” or the “company”) today announced that it has received a $225 million payment which was due from ipsen, s.a. as a result of its receipt of approval from the u.s. food and drug administration, or fda, to market onivyde as a first-line treatment of metastatic adenocarcinoma on the pancreas. merrimack's board of directors has evaluated the likelihood of receiving additional milestone payments under the i.
2024-03-07 16:30:00 - Press Release
Merrimack Reports Full Year 2023 Financial Results
Cambridge, mass.--(business wire)--merrimack reports full year 2023 financial results.
2024-02-13 16:18:00 - Press Release
Merrimack Reports Ipsen Announcement Of Approval By The Us Fda Of Onivyde® (irinotecan Liposome Injection) Plus 5 Fluorouracil/leucovorin And Oxaliplatin (nalirifox) As A First-line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma (mpdac)
Cambridge, mass.--(business wire)--merrimack pharmaceuticals, inc. (nasdaq: mack) (“merrimack” or the “company”) reported that ipsen, sa (“ipsen”) issued a press release today announcing the u.s. food and drug administration has approved the supplemental new drug application for onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (nalirifox) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mpdac). under the terms o.
2023-11-02 16:30:00 - Press Release
Merrimack Reports Third Quarter 2023 Financial Results
Cambridge, mass.--(business wire)--merrimack reports third quarter 2023 financial results.
2023-08-03 16:30:00 - Press Release
Merrimack Reports Second Quarter 2023 Financial Results
Cambridge, mass.--(business wire)--merrimack reports second quarter 2023 financial results.
Latest News
2023-01-04 10:33:10 - Seeking Alpha
Merrimack Still Has Significant Arbitrage Potential
In December 2022, MACK got positive clinical results for its Phase III clinical trial of Onivyde in first line pancreatic cancer. A $225m milestone from Ipsen will be triggered on approval, which corresponds to about $16.75 per basic share.
2022-11-09 13:12:43 - Pulse2
Merrimack Pharmaceuticals (MACK) Stock Skyrockets Over 240%: Details
The stock price of Merrimack Pharmaceuticals (MACK) skyrocketed by over 240% today. This is why.
2022-11-09 10:13:15 - Market Watch
Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment
Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% IPN, +3.85% said overnight that its Onivyde pancreatic cancer treatment met the primary endpoint of a Phase 3 trial. Ipsen said it plans to file a supplemental New Drug Application (NDA) with the U.S. Food and Drug Administration for Onivyde.
2022-10-31 09:00:00 - Seeking Alpha
Return Of The Mack: A Deeply Misunderstood Near-Term Readout
MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cancer drugs are targeted therapies that fail in the clinic.
2021-08-05 16:30:00 - Business Wire
Merrimack Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 2021. “We are pleased to report continued reductions in our operating expenses as well as positive overall cashflow during the quarter due to receipt of a tax refund,” said Gary Crocker, Chairman of Merrimack's Board of Directors. “Both Ipsen Pharmaceuticals and Elevation Oncology continue to repor
2021-03-10 18:00:00 - Business Wire
Merrimack Reports Full Year 2020 Financial Results
2020-08-07 12:20:00 - Yahoo
Merrimack Reports Second Quarter 2020 Financial Results
2020-08-07 00:00:00 - businesswire
Merrimack Reports Second Quarter 2020 Financial Results
2020-08-05 12:33:44 - Yahoo
We Think Merrimack Pharmaceuticals (NASDAQ:MACK) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
2020-07-27 04:44:49 - https://www.thelincolnianonline.com
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Insider Sells $363,326.04 in Stock
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider Gary L. Crocker sold 117,963 shares of Merrimack Pharmaceuticals stock in a transaction that occurred on Wednesday, July 22nd. The shares were sold at an average price of $3.08, for a total transaction of $363,326.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which […]